Skip to main content

Table 3 KI benefit response after the second treatment cycle (worst case scenario)

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

  KI benefit response a All patients (N = 521) n (%) of patients [95% CI]
Responders overall 302 (58.0) [53.6; 62.2]
   0% improvement of KI, but maintained ≥ 80% 151 (29.0)
   10% improvement of KI 97 (18.6)
   20% improvement of KI 7 ( 1.3)
   30% improvement of KI 2 ( 0.4)
   Worsening of KI, but still maintained ≥ 80% 45 ( 8.6)
Non-responders, overall 219 (42.0) [37.8; 46.4]
   0% worsening of KI, but maintained < 80% 67 (12.9)
   Deterioration of KI, developed KI < 80% 102 (19.6)
   Missing data b 50 ( 9.6)
  1. CI confidence interval, KI Karnofsky Index, N = total number of patients, n = number of patients
  2. a) Defined as improvement in KI of at least 10% (absolute) or maintenance/achievement of an absolute KI of at least 80%
  3. b) Patients who discontinued prior to the end of the second treatment cycle or who had missing KI data were considered as non-responders (worst case scenario)
\